Your shopping cart is currently empty

ATF3-IN-1 is an inhibitor of both ferroptosis and ATF3. It mitigates oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, offering protection against ischemic stroke. ATF3-IN-1 can reduce ischemia/reperfusion (I/R) injury and enhance neuron survival, demonstrating neuroprotective effects, making it valuable for ischemic stroke research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | ATF3-IN-1 is an inhibitor of both ferroptosis and ATF3. It mitigates oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, offering protection against ischemic stroke. ATF3-IN-1 can reduce ischemia/reperfusion (I/R) injury and enhance neuron survival, demonstrating neuroprotective effects, making it valuable for ischemic stroke research. |
| In vitro | ATF3-IN-1 (Compound 1c) at concentrations of 0.1-2 μM alleviates ischemia/reperfusion (I/R) injury in primary cortical neuron models of oxygen-glucose deprivation (OGD) by inhibiting oxidative stress and ferroptosis. It exhibits no cytotoxicity in rat cortical neurons not subjected to OGD. ATF3-IN-1 mitigates ferroptosis and reduces I/R injury in the primary cortical neuron OGD model through the ATF3/SLC7A11/GPX4 axis. |
| In vivo | ATF3-IN-1 (Compound 1c) (2 mg/kg, ICV, single administration) reduces infarct volume and promotes neurological recovery after brain ischemia/reperfusion (I/R) injury in a rat model of middle cerebral artery occlusion (MCAO) by modulating the ATF3/SLC7A11/GPX4 axis, oxidative stress, and ferroptosis. |
| Molecular Weight | 451.55 |
| Formula | C24H37NO7 |
| Cas No. | 2952703-90-9 |
| Smiles | O=C1C(OC)=C(OC)C(=O)C(=C1C)CCCCCCCCCCOC(=O)N2CCOCC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.